Leishmania (Cutaneous, Mucosal, or Visceral Leishmaniasis) - Microscopy and PCR
Conformément au Règlement de l’Ontario 671/92 de la Loi sur les services en français, les renseignements d’analyses de laboratoire liés à la présente page ne sont offerts qu’en anglais parce qu’ils sont de nature scientifique ou technique et destinés uniquement à l’usage des fournisseurs de soins de santé qualifiés et non aux membres du public.
Background
This page provides routine microscopy and PCR testing information for leishmaniasis at Public Health Ontario (PHO). The causative agent of leishmaniasis is the genus Leishmania. Manifestations include cutaneous leishmaniasis (CL), mucosal leishmaniasis (ML), and visceral leishmaniasis (VL, also known as kala azar).
This page is for information limited to microscopy and PCR. For serology, please refer to the following PHO webpage:
Updates
This page was updated to include the following changes:
- travel history added as a mandatory acceptance criterion;
- turnaround time expectations revised from business days to calendar days;
- a change from end-point to real-time PCR for Viannia kDNA target;
- additional details regarding performance/limitations added as well as result interpretation;
- and the algorithm for species identification referral was updated to NRCP instead of the US CDC.
Testing Indications
CL and ML: PCR is the main diagnostic test method and should be requested whenever either disease is suspected. Microscopic examination is helpful when positive but has poor sensitivity in CL and ML. Serology has limited value in CL and ML and should not be routinely requested.1
VL: Microscopy and PCR are the main diagnostic test methods and should be requested whenever VL is suspected. Serology is an adjunct but not a replacement for microscopy and PCR in VL.1
Acceptance/Rejection Criteria
Specimens submitted without relevant clinical or exposure information (including travel history) may be delayed or rejected.
Specimen Requirements
| Test Requested | Required Requisition(s) | Specimen Type | Minimum Volume | Collection Kit |
Leishmania, cutaneous leishmaniasis, or mucosal leishmaniasis |
Lesion brushing/ swabbing
Lesion scraping
Lesion aspirate
Filter paper lesion impression
Lesion biopsy |
N/A
N/A
0.1 ml sterile saline
Filter paper
~2-4 mm punch biopsy |
Sterile container |
|
Leishmania, visceral leishmaniasis, or kala azar |
Whole blood in Ethylenediaminetetraacetic acid (EDTA ) Splenic, bone marrow, or lymph node aspirate Bone marrow, lymph node, or liver biopsy |
4.0 ml
1.0 ml
N/A |
EDTA tube
EDTA tube or sterile container
Sterile container |
|
Leishmania |
Formalin-fixed paraffin-embedded (FFPE) tissue blocks with accompanying histology stained slides |
N/A |
FFPE block and slides(s) |
Submission and Collection Notes
See Special Instructions below for suggestions on specimen collection for CL and ML.
Complete all fields of the requisition form
Travel history – the country/region of exposure MUST be stated otherwise testing may be delayed or cancelled.
Label the specimen container(s) with the patient’s first and last name, date of collection, and one other unique identifier such as the patient’s date of birth or Health Card Number. Failure to provide this information may result in rejection or testing delay.
Storage and Transport
Place specimen in biohazard bag and seal. Specimens should be stored at room temperature following collection and shipped to PHO’s laboratory as soon as possible. All clinical specimens must be shipped in accordance to the Transportation of Dangerous Good Act.
Special Instructions
CL or ML: To increase the likelihood of detection, collect multiple specimens from the most active areas (e.g. oozing ulcer base and advancing inflammatory margins) of each lesion using different techniques as below. Avoid healed areas or areas with secondary bacterial/fungal infection. Clean affected areas with 70% alcohol (not iodine) and remove overlying necrotic debris/scabs. If needed, a low concentration of local anesthetics (e.g. 1% lidocaine) can be used to reduce discomfort.
- If using lesion scraping technique: scrape most active areas (without making incision; bleeding should be minimal but oozing may occur) and transfer scraped material into a sterile container with minimal amount of sterile saline to keep material moistened during transit.
- If using lesion brushing/swabbing technique: brush most active areas multiple times until pink-tinged tissue fluids are wicked onto brush/swab and transfer brush/swab into a sterile container with minimal amount of sterile saline keep material moistened during transit.
- If using lesion aspirate technique: using 0.1-0.2 ml of sterile saline and a 23- to 27-gauge needle, gently insert and rotate the needle back and forth tangentially in the most active area while aspirating pink-tinged tissue fluids up to the needle hub (note: if insufficient fluid is obtained, inject 0.05-0.1 ml of sterile saline in the area and resume suction) and transfer aspirated fluid into a sterile container.
- If using filter paper lesion impression technique: using sterile coarse-porosity 7-cm filter paper, gently press paper onto ulcer base multiple times to cover ulcer surface until pink-tinged tissue fluids are wicked onto the paper and transfer paper into a sterile container.
- If using lesion biopsy technique: obtain a 2-4 mm punch biopsy of the most active area (down to the level of the dermis) and transfer biopsied material into a sterile container with minimal amount of sterile saline to keep material moistened during transit.
Note that PCR sensitivity varies by cutaneous or mucosal lesion type, lesion severity, collection technique, lesion area sampled, and Leishmania species. Boggild et al.2,3 reported comparable sensitivity between filter paper impressions (86.6-92.3%) and aspirates or scrapings (92.5-94.2%). Valencia et al.4 similarly reported comparable sensitivity between filter paper impressions (99.1%), foam swabs (99.1%), and scrapings (96.6%). Boggild et al.5 reported comparable sensitivity between foam swabs (95.7%) and biopsy specimens (95.7%). Adams et al.6 reported superior sensitivity of foam swabs (97.5%) versus aspirates (80%). Blaizot et al.7 reported superior sensitivity of post-biopsy cotton swabs (98%) versus biopsy specimens (89%). Suarez et al.8 reported superior parasite loads at the ulcer base compared to the raised border, as well as superior parasite loads using foam swabs or scrapings versus biopsies.
VL: PCR sensitivity also varies by specimen type and Leishmania species. Although splenic aspirates are usually considered of highest yield, their collection is a high-risk procedure, and blood and bone marrow specimens alternatively also have high accuracy (93.1-95.3% sensitivity and 92.6-95.6% specificity per de Ruiter et al.9).
Test Frequency and Turnaround Time (TAT)
Leishmania PCR and microscopy are performed Monday to Friday at PHO’s Toronto laboratory site.
Turnaround time is up to 3 calendar days for PCR and 5 calendar days for microscopy from receipt at PHO.
If strongly positive by PCR, samples are forwarded to the National Reference Centre for Parasitology (NRCP) in Montreal for species identification. Turnaround time for species identification is up to 42 calendar days.
Leishmania PCR detection is performed at PHO using three different laboratory-developed assays performed in parallel: a genus-level 18s rRNA gene real-time PCR (Wortmann et al.9), a Leishmania Leishmania subgenus kDNA real-time PCR (Mary et al.10), and a Leishmania Viannia subgenus kDNA real-time PCR(Lopez et al.11).
Leishmania microscopy is performed at PHO using Giemsa staining. Whole blood specimens undergo buffy coat concentration.
Leishmania species identification is performed at the NRCP
Performance and Limitations
At PHO, microscopy has an overall sensitivity of 27% and specificity of 100% (Lau et al.14). The 18s rRNA gene real-time PCR has 95% sensitivity for the Leishmania genus but does not differentiate between Leishmania (L.) and Leishmania (V.) subgenera. The Leishmania (L.) subgenus kDNA real-time PCR has > 95% sensitivity for the Leishmania (L.) subgenus with around 25% cross-reactivity with Leishmania (V.) species at higher cycle threshold values. For L. (L.) amazonensis and L. (L.) tropica however, the Leishmania (L.) kDNA target sensitivity may be inferior compared to 18s rRNA gene target sensitivity due to sequence mismatches. The Leishmania (V.) kDNA real-time PCR has > 95% sensitivity for the Viannia subgenus with no cross-reactivity with the Leishmania subgenus. Both kDNA assays may cross-react with other organisms including Trypanosoma species. The performance of either 18s rRNA gene or kDNA PCR targets for rarer Leishmania species, including Leishmania Mundinia sugenus, has not yet been established.
The NRCP species identification assays may be unable to provide identification at low parasite loads.
Algorithm
PCR is performed on all specimens received. If PCR is positive with a strong enough signal (18s rRNA cycle threshold value < 30), the specimen will be automatically forwarded to the NRCP for further Leishmania species identification, otherwise species identification will not be performed.
Microscopy is only performed if specifically requested on the requisition.
Interpretation
PCR detection results:
Leishmania genus |
Leishmania (Leishmania) kDNA target |
Leishmania (Viannia) kDNA target |
Reported PCR Interpretation |
Comment |
|---|---|---|---|---|
Positive |
Positive |
Negative |
Detected* |
Results suggest L. subgenus Leishmania infection. |
Positive |
Weak positive or negative |
Positive |
Detected* |
Results suggest L. subgenus Viannia infection. |
Strong positive |
Negative |
Negative |
Detected* |
Unable to distinguish subgenus. |
Weak positive |
Negative |
Negative |
Indeterminate |
Result is inconclusive. Repeat collection if clinically indicated. |
Negative |
Negative |
Negative |
Negative |
If only one specimen was submitted, repeat collection may be advised if clinically indicated. |
Invalid |
Invalid |
Invalid |
Invalid |
Testing unable to proceed due to failed detection of assay control(s). Repeat collection if clinically indicated. |
Microscopy results (if requested):
| Parasite Microscopy | Interpretation |
|---|---|
Amastigotes detected. |
Unable to distinguish Leishmania from Trypanosoma cruzi amastigotes by microscopy. |
No amastigotes detected. |
Negative microscopy results do not rule out leishmaniasis. PCR has superior sensitivity over microscopy. |
Reporting
Results are reported to the physician, authorized health care provider (General O. Reg 45/22, s.18) or submitter as indicated on the requisition.
References
- Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, Carvalho EM, Ephros M, Jeronimo S, Magill A. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016 Dec 15;63(12):1539-1557. doi: 10.1093/cid/ciw742. PMID: 27941143.
- Boggild AK, Valencia BM, Espinosa D, Veland N, Ramos AP, Arevalo J, et al. Detection and species identification of Leishmania DNA from filter paper lesion impressions for patients with American cutaneous leishmaniasis. Clin Infect Dis. 2010;50(1):e1-6. Available from: https://doi.org/10.1086/648730
- Boggild AK, Ramos AP, Valencia BM, Veland N, Calderon F, Arevalo J, et al. Diagnostic performance of filter paper lesion impression PCR for secondarily infected ulcers and nonulcerative lesions caused by cutaneous leishmaniasis. J Clin Microbiol. 2011;49(3):1097-100. Available from: https://doi.org/10.1128/JCM.02457-10
- Valencia BM, Veland N, Alba M, Adaui V, Arevalo J, Low DE, et al. Non-invasive cytology brush PCR for the diagnosis and causative species identification of American cutaneous leishmaniasis in Peru. PLoS One. 2012;7(11):e49738. Available from: https://doi.org/10.1371/journal.pone.0049738
- Boggild AK, Valencia BM, Veland N, Pilar Ramos A, Calderon F, Arevalo J, et al. Non-invasive cytology brush PCR diagnostic testing in mucosal leishmaniasis: superior performance to conventional biopsy with histopathology. PLoS One. 2011;6(10):e26395. Available from: https://doi.org/10.1371/journal.pone.0026395
- Adams ER, Gomez MA, Scheske L, Rios R, Marquez R, Cossio A, et al. Sensitive diagnosis of cutaneous leishmaniasis by lesion swab sampling coupled to qPCR. Parasitology. 2014;141(14):1891-7. Available from: https://doi.org/10.1017/S0031182014001280
- Blaizot R, Simon S, Ginouves M, Prévot G, Blanchet D, Ravel C, et al. Validation of swab sampling and SYBR green-based real-time PCR for the diagnosis of cutaneous leishmaniasis in French Guiana. J Clin Microbiol. 2021;59(2):e02218-20. Available from: https://doi.org/10.1128/JCM.02218-20
- Suárez M, Valencia BM, Jara M, Alba M, Boggild AK, Dujardin JC, et al. Quantification of Leishmania (Viannia) kinetoplast DNA in ulcers of cutaneous leishmaniasis reveals inter-site and inter-sampling variability in parasite load. PLoS Negl Trop Dis. 2015;9(7):e0003936. Available from: https://doi.org/10.1371/journal.pntd.0003936
- de Ruiter CM, van der Veer C, Leeflang MM, Deborggraeve S, Lucas C, Adams ER. Molecular tools for diagnosis of visceral leishmaniasis: systematic review and meta-analysis of diagnostic test accuracy. J Clin Microbiol. 2014;52(9):3147-55. Available from: https://doi.org/10.1128/JCM.00372-14
- Wortmann G, Sweeney C, Houng HS, Aronson N, Stiteler J, Jackson J, et al. Rapid diagnosis of leishmaniasis by fluorogenic polymerase chain reaction. Am J Trop Med Hyg. 2001;65(5):583-7. Available from: https://doi.org/10.4269/ajtmh.2001.65.583
- Mary C, Faraut F, Lascombe L, Dumon H. Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J Clin Microbiol. 2004;42(11):5249-55. Available from: https://doi.org/10.1128/JCM.42.11.5249-5255.2004
- Lopez M, Inga R, Cangalaya M, Echevarria J, Llanos-Cuentas A, Orrego C, et al. Diagnosis of Leishmania using the polymerase chain reaction: a simplified procedure for field work. Am J Trop Med Hyg. 1993;49(3):348-56. Available from: https://doi.org/10.4269/ajtmh.1993.49.348
- Lau R, Valencia B, Ralevski F, Llanos-Cuentas A, Boggild AK. Validation of a molecular diagnostic algorithm for leishmania detection in a non-endemic setting. Int J Infect Dis. 2014;21(1):162-3. Available from: https://doi.org/10.1016/j.ijid.2014.03.761
Vous n'avez pas de compte MonSPO? S'inscrire maintenant